Cadila Healthcare Launches Drug for Breast Cancer Treatment
Global pharmaceutical company, Cadila Healthcare has announced the launch of Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar for treating both early and advanced HER2 positive breast cancer. The company will market the drug under the brand name Ujvira. HER2 positive breast cancer is considered an aggressive form and constitutes 20 to 25% of…